眼下，禾木(中国)生物工程有限公司还在针对颅内血管粥样硬化导致的慢性狭窄研发药物球囊导管 和药物支架，预计2027年获批上市，并有望成为全球首个上市的脑血管药物球囊和药物支架产品。 医药医疗器械产业链是威海十条优势产业链之一，链上企业规模达到了216家。为了推进高端医疗 器械原始创新策源地和成果转化孵化高地建设，威海累计建成各类创新平台104家，打造的省高端医疗 器械领域创新创业共同体已汇聚创新主体99家，组织开展技术攻关项目59个，突破关键技术88项，100 多种产品实现国产替代。 眼下，在位于威海南海新区的威海德尔自动化设备有限公司里，工人们正紧张忙碌地赶制定制机 床。其中，刚下线的九轴五联动机床格外引人注目，这款曾长期被日本、德国企业垄断的高端设备，如 今已实现国产化自主设计生产。 威海德尔自动化设备有限公司是一家生产高档精密数控机床及智能化生产线为主的高新技术型企 业。近年来，该公司始终将研发放在重要位置，每年将营收的10%投入研发。今年，公司更是加大投 入，在数月内陆续攻克了30多项关键技术，生产业内最顶级的九轴机床产品。"这是我们首台套九轴机 床订单，技术复杂度和生产难度都是目前最高的，后续还有三 ...

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]